Repository logo
HARVEST
 

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern

Simple item page
dc.contributor.authorGarg, Ravendra
dc.contributor.authorLiu, Qiang
dc.contributor.authorKessel, Jill Van
dc.contributor.authorAsavajaru, Akarin
dc.contributor.authorUhlemann, Eva-Maria
dc.contributor.authorJoessel, Morgane
dc.contributor.authorHamonic, Glenn
dc.contributor.authorkhatooni, zahed
dc.contributor.authorKroeker, Andrea
dc.contributor.authorLew, Jocelyne
dc.contributor.authorScruten, Erin
dc.contributor.authorPennington, Paul
dc.contributor.authorDeck, William
dc.contributor.authorPrysliak, Tracy
dc.contributor.authorNickol, Michaela
dc.contributor.authorApel, Falko
dc.contributor.authorCourant, Thomas
dc.contributor.authorKelvin, Alyson A.
dc.contributor.authorKessel, Andrew Van
dc.contributor.authorCollin, Nicolas
dc.contributor.authorGerdts, Volker
dc.contributor.authorKöster, Wolfgang
dc.contributor.authorFalzarano, Darryl
dc.contributor.authorRacine, Trina
dc.contributor.authorBanerjee, Arinjay
dc.date.accessioned2025-05-09T17:44:00Z
dc.date.available2025-05-09T17:44:00Z
dc.date.issued2024-05
dc.description.abstractThe emergence and ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for rapid vaccine development platforms that can be updated to counteract emerging variants of currently circulating and future emerging coronaviruses. Here we report the development of a “train model” subunit vaccine platform that contains a SARS-CoV-2 Wuhan S1 protein (the “engine”) linked to a series of flexible receptor binding domains (RBDs; the “cars”) derived from SARS-CoV-2 variants of concern (VOCs). We demonstrate that these linked subunit vaccines when combined with Sepivac SWE™, a squalene in water emulsion (SWE) adjuvant, are immunogenic in Syrian hamsters and subsequently provide protection from infection with SARS-CoV-2 VOCs Omicron (BA.1), Delta, and Beta. Importantly, the bivalent and trivalent vaccine candidates offered protection against some heterologous SARS-CoV-2 VOCs that were not included in the vaccine design, demonstrating the potential for broad protection against a range of different VOCs. Furthermore, these formulated vaccine candidates were stable at 2–8 °C for up to 13 months post-formulation, highlighting their utility in low-resource settings. Indeed, our vaccine platform will enable the development of safe and broadly protective vaccines against emerging betacoronaviruses that pose a significant health risk for humans and agricultural animals.
dc.description.sponsorshipThis study was funded by a grant from the Coalition for Epidemic Preparedness Innovations (CEPI). D.F. acknowledges funding from the Canadian Institutes of Health Research (PJT – 153319; VS1-175531). A.B. acknowledges funding from the Canadian Institutes of Health Research (CIHR)-Centre for Research on Pandemic Preparedness and Health Emergencies, Early Career Investigator Grant (FRN: PEE-183995). The authors would also like to thank the Vaccine Formulation Institute (VFI) for their collaboration and VIDO’s veterinary staff for their tremendous efforts. VIDO receives operational funding from the Canada Foundation for Innovation through the Major Science Initiatives, from the Government of Saskatchewan through Innovation Saskatchewan, and the Ministry of Agriculture. Some figures were generated using BioRender.com.
dc.description.versionPeer Reviewed
dc.identifier.citationGarg, R., Liu, Q., Van Kessel, J., Asavajaru, A., Uhlemann, E.-M., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., Lew, J., Scruten, E., Pennington, P., Deck, W., Prysliak, T., Nickol, M., Apel, F., Courant, T., Kelvin, A. A., Van Kessel, A., … Banerjee, A. (2024). Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern. Vaccine, 42(20), 125980–125980. https://doi.org/10.1016/j.vaccine.2024.05.028
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2024.05.028
dc.identifier.urihttps://hdl.handle.net/10388/16924
dc.language.isoen
dc.publisherScienceDirect
dc.rightsAttribution 2.5 Canadaen
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/ca/
dc.subjectSARS-CoV-2
dc.subjectbetacoronaviruses
dc.subjectagricultural animals
dc.titleEfficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Garg_etal_Subunit_Vaccine_Platform.pdf
Size:
3.3 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.36 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

VIDO-InterVac
One Health